EPA, Justice Dept. Seek Civil Penalties In East Palestine Wreck
FDA Authorizes Updated COVID-19 Vaccines Targeting Omicron Subvariant
August 31, 2022
by Dan McCue
WASHINGTON — The Food and Drug Administration on Wednesday authorized updated COVID-19 booster shots specifically targeting a subvariant of omicron.
The agency approved two options aimed at the BA.5 subvariant of omicron that is now dominant in the U.S.: one made by Pfizer and its German partner BioNTech for use in people as young as 12; the other, manufactured by Moderna, for those 18 and older.
Wednesday’s authorization allows the use of the new bivalent formulations of the vaccines as a single booster dose at least two months following primary or booster vaccination.
Both represent the first major redesign of the COVID vaccines since they were initially injected into arms in December 2020.
The updated boosters include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19 and an mRNA component in common between the omicron subvariants BA.4 and BA.5 lineages to provide better protection against COVID-19 caused by the omicron variant.
The BA.4 and BA.5 lineages of the omicron variant are currently causing most cases of COVID-19 in the U.S. and are predicted to circulate this fall and winter.
The doses can be given at least two months after people last received a booster dose or completed their initial series of vaccinations.
“As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose,” Dr. Robert M. Califf, the F.D.A. commissioner, said in a written statement.
He added that the newly formulated vaccine would “provide better protection against currently circulating variants.”
But the approval of the new vaccines didn’t come without some push back from members of the FDA advisory committee that reviewed their efficacy.
The concern mainly revolves around the speed at which the new vaccines were turned around — the FDA advised the companies only two months ago on the formulation that they should adopt for the new vaccines — and the resulting lack of human trials.
Both Pfizer and Moderna went to federal regulators this summer with more limited data on the redesigned boosters than a traditional review process would call for — instead of human trials, they presented the outcome of tests of the new vaccines on mice.
Last week, Dr. Paul Offit, a member of the FDA advisory committee, told The Well News he was, at best, skeptical of the data the pharmaceutical companies have presented.
“As a famous vaccinologist at the Wistar Institute says: ‘Mice lie and monkeys exaggerate,’” he said, referring to the independent, nonprofit research institution in Philadelphia.
“You can’t use mice to predict events in people. You just can’t,” Offit said. “I mean, let me put it this way, if mouse studies were predictive of outcomes in people, we would have had an AIDS vaccine 30 years ago.
“The bottom line is, mice aren’t people. They have a different genome … and while they help sort of point you in the right direction … I just don’t think tests on mice can be used as a proof that something is going to be valuable that you’re about to give to millions of people. I just don’t think that’s adequate. And I think that the American public deserves more data than what we’ve been given,” he said.
But others argue that because the coronavirus is evolving so quickly, human trials would be out of date long before a formal authorization could be handed down.
According to the Centers for Disease Control and Prevention, the number of COVID cases, deaths and hospitalizations are all trending lower.
As of Wednesday morning, the daily average of new cases wass 82,475, with the average daily number of deaths being 387, and the average daily new admissions to hospitals being 5,255.
Vaccinations continue to be at the heart of the Biden administration’s COVID response strategy.
The White House has already ordered over 170 million doses of the new vaccine for a fall booster campaign, and, now that the FDA has weighed in, expects those boosters to reach the states in a matter of days.
Dan can be reached at dan@thewellnews.com and at https://twitter.com/DanMcCue.
In The News
Health
Voting
Health
March 31, 2023
by Dan McCue
EPA, Justice Dept. Seek Civil Penalties In East Palestine Wreck
WASHINGTON — The Environmental Protection Agency, in coordination with the U.S. Justice Department, is seeking potentially millions of dollars in... Read More
WASHINGTON — The Environmental Protection Agency, in coordination with the U.S. Justice Department, is seeking potentially millions of dollars in civil fines from the Norfolk Southern Railway Co. in connection to the Feb. 3 derailment of a train carrying hazardous materials near East Palestine, Ohio. In... Read More
March 31, 2023
by Kate Michael
Analysts Blame Farm Runoff for Toxic Algae Blooms
WASHINGTON — Americans starting to think about spring and summer vacations as the weather warms may find their favorite water... Read More
WASHINGTON — Americans starting to think about spring and summer vacations as the weather warms may find their favorite water destinations unsafe for swimming. Thick layers of cyanobacteria — commonly known as blue-green algae — have closed popular local lakes in recent years, and Florida has... Read More
March 30, 2023
by Transgender Visibility Saves Lives in the Clinic, Too
Transgender Visibility Saves Lives in the Clinic, Too
The overwhelming evidence and consensus among global health organizations is that gender-affirming care saves lives. Yet many transgender, nonbinary and... Read More
The overwhelming evidence and consensus among global health organizations is that gender-affirming care saves lives. Yet many transgender, nonbinary and gender non-conforming people lack access to the care they need. Some must wait up to a year to talk to a medical professional about gender-affirming care.... Read More
March 29, 2023
by Dan McCue
Increased Telehealth Use Reduced Overdose Risk During Pandemic
WASHINGTON — An increased reliance on telehealth services and medications for opioid use disorder by Medicare beneficiaries significantly reduced their... Read More
WASHINGTON — An increased reliance on telehealth services and medications for opioid use disorder by Medicare beneficiaries significantly reduced their risk for fatal overdoses during the COVID-19 pandemic, the National Center for Injury Prevention and Control reported on Wednesday. Published in JAMA Psychiatry, the study is... Read More
Fundraising Over Solutions: Women’s Health and a Missed Opportunity Post-Dobbs
In June 2022 the U.S. Supreme Court issued a decision that provided the sought after political fodder to catapult fundraising... Read More
In June 2022 the U.S. Supreme Court issued a decision that provided the sought after political fodder to catapult fundraising efforts heading into the 2022 midterm election cycle. In the June opinion, the court overruled two cases from 1973 and 1992, and returned the matter of... Read More
March 29, 2023
by Dan McCue
Budzinski Joins Overdose, Addiction Working Groups
WASHINGTON — Rep. Nikki Budzinski, D-Ill., has joined the Bipartisan Fentanyl Prevention Caucus and the Bipartisan Mental Health and Substance... Read More
WASHINGTON — Rep. Nikki Budzinski, D-Ill., has joined the Bipartisan Fentanyl Prevention Caucus and the Bipartisan Mental Health and Substance Use Disorder Task Force where, she says, she will work across the aisle on solutions to the ongoing addiction crisis. “Every day, too many of our... Read More
News From The Well
